Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Felix W Frueh

Showing results (1-10 of 30) with videos related to

Pageof 3
Sort By:
Pharmacogenomics|July 17, 2009
Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicineFelix W Frueh
Drug Discovery Today|October 4, 2011
Considerations for safety pharmacogenetics in clinical practiceFelix W Frueh
Trends in Molecular Medicine|March 3, 2012
On rat poison and human medicines: personalizing warfarin therapyFelix W Frueh
Pharmacogenomics|April 27, 2010
Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practiceFelix W Frueh
Personalized Medicine|May 24, 2018
Considerations for a business model for the effective integration of novel biomarkers into drug developmentFelix W Frueh
Nature Biotechnology|September 12, 2006
Impact of microarray data quality on genomic data submissions to the FDAFelix W Frueh
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 17, 2013
Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United StatesFelix W Frueh
Pharmacogenomics|June 24, 2004
From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the communityFelix W Frueh, David Gurwitz
Expert Review of Molecular Diagnostics|August 12, 2014
Molecular diagnostics clinical utility strategy: a six-part frameworkFelix W Frueh, Bruce Quinn
Environmental and Molecular Mutagenesis|June 15, 2007
Implementing the U.S. FDA guidance on pharmacogenomic data submissionsFederico Goodsaid, Felix W Frueh
Pageof 3

Showing results (1-10 of 30) with videos related to

Sort By:
Pageof 3
Pharmacogenomics|July 17, 2009
Back to the future: why randomized controlled trials cannot be the answer to pharmacogenomics and personalized medicineFelix W Frueh
Drug Discovery Today|October 4, 2011
Considerations for safety pharmacogenetics in clinical practiceFelix W Frueh
Trends in Molecular Medicine|March 3, 2012
On rat poison and human medicines: personalizing warfarin therapyFelix W Frueh
Pharmacogenomics|April 27, 2010
Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practiceFelix W Frueh
Personalized Medicine|May 24, 2018
Considerations for a business model for the effective integration of novel biomarkers into drug developmentFelix W Frueh
Nature Biotechnology|September 12, 2006
Impact of microarray data quality on genomic data submissions to the FDAFelix W Frueh
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 17, 2013
Regulation, reimbursement, and the long road of implementation of personalized medicine--a perspective from the United StatesFelix W Frueh
Pharmacogenomics|June 24, 2004
From pharmacogenetics to personalized medicine: a vital need for educating health professionals and the communityFelix W Frueh, David Gurwitz
Expert Review of Molecular Diagnostics|August 12, 2014
Molecular diagnostics clinical utility strategy: a six-part frameworkFelix W Frueh, Bruce Quinn
Environmental and Molecular Mutagenesis|June 15, 2007
Implementing the U.S. FDA guidance on pharmacogenomic data submissionsFederico Goodsaid, Felix W Frueh
Pageof 3